c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Leritrelvir reduces COVID-19 risk: real-time meta-analysis of 3 studies

@CovidAnalysis, November 2026, Version 2V2 (V1 2024)

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Leritrelvir COVID-19 outcomes

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wang (DB RCT)35%0.65 · 0.43–0.97recov. time20 (n)20 (n) Wang (DB RCT)21%0.79 · 0.67–0.95viral load20 (n)20 (n) Wang (DB RCT)11%0.89 · 0.74–1.07viral load20 (n)20 (n) Wang (DB RCT)52%0.48 · 0.22–1.00viral+20 (n)20 (n) Wang (DB RCT)80%0.20 · 0.09–0.45viral+20 (n)20 (n) Zhan (DB RCT)17%0.83 · 0.74–0.93no recov.680 (n)679 (n) Zhan (DB RCT)14%0.86 · 0.77–0.97no recov.680 (n)679 (n) Zhan (DB RCT)21%0.79 · 0.63–0.98no recov.111/680141/679 Zhan (DB RCT)22%0.78 · 0.60–1.01no recov.89/680114/679 Zhan (DB RCT)16%0.84 · 0.73–0.96viral+231/680275/679 Cheng40%0.60 · 0.50–0.72no recov.1,388 (n)139 (n) Cheng (PSM)45%0.55 · 0.44–0.70no recov.136 (n)136 (n) Cheng (PSM)25%0.75 · 0.68–0.83recov. time136 (n)136 (n) Cheng18%0.82 · 0.68–0.99viral+1,388 (n)139 (n) Cheng (PSM)32%0.68 · 0.56–0.83viral+136 (n)136 (n) Cheng (PSM)25%0.75 · 0.61–0.92viral time136 (n)136 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Leritrelvir
reduces riskLeritrelvir
increases risk →

Fig. S1. All outcomes.

Loading..

Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.